ContraVir Pharmaceuticals Announces $9.0 Million Private Placement
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement
New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.
Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw, a unit of H.C Wainwright, in a $3.9 Million Public Offering of Medical Transcript Billing, Corp. - December 11, 2017
- Happy Holidays from Sichenzia Ross Ference Kesner! - December 9, 2017
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $6.58 Million Registered Direct Offering and Concurrent Private Placement - December 6, 2017